113/12/27 19:00 - 20:30

-

線上課程

時段	主題	講師	主持人
19:00~20:30	Advances in the Treatment of Diabetic Kidney Disease : Current Concept and Future Perspectives	鍾牧圻 醫師 台中榮總	黃尚志 醫師 高醫附醫

●Diabetic Kidney Disease (DKD) is a leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) globally. It significantly increases the risk of cardiovascular morbidity and mortality. In recent years, the management of DKD has evolved from conventional glucose and blood pressure control to a more comprehensive approach targeting multiple pathophysiological pathways. This summary highlights the current therapeutic options and future directions in DKD treatment.
1. Angiotensin Receptor Blockers (ARBs)
ARBs, such as losartan and irbesartan, remain a cornerstone in DKD management due to their ability to inhibit the renin-angiotensin-aldosterone system (RAAS). They effectively reduce proteinuria and slow the progression of kidney function decline. Despite these benefits, their protective effects are often insufficient to halt disease progression, necessitating combination therapies.
2. Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i)
SGLT2 inhibitors, including empagliflozin and dapagliflozin, have revolutionized DKD treatment. Beyond glycemic control, they confer significant renoprotective and cardioprotective effects by lowering intraglomerular pressure, reducing albuminuria, and mitigating inflammation. Landmark trials such as DAPA-CKD and EMPA-KIDNEY have expanded their use to CKD patients regardless of diabetes status.
3. Third-Generation Mineralocorticoid Receptor Antagonists (3rd MRA)
Finerenone, a novel selective mineralocorticoid receptor antagonist, has demonstrated substantial benefits in reducing proteinuria, slowing kidney disease progression, and lowering cardiovascular risk in DKD patients. The FIDELIO-DKD and FIGARO-DKD trials confirmed its efficacy with a favorable safety profile, particularly concerning hyperkalemia.
4. GLP-1 Receptor Agonists (GLP-1 RA)
GLP-1 receptor agonists, such as liraglutide and semaglutide, offer dual benefits of glycemic control and cardiovascular protection. Emerging evidence suggests they also have renoprotective effects, including reduced albuminuria and potential anti-inflammatory and antifibrotic actions, making them a valuable addition to DKD management.
●Conclusion and Future Perspectives
The current therapeutic landscape for DKD emphasizes a multifaceted approach, incorporating RAAS inhibition, SGLT2i, MRAs, and GLP-1 RAs. Future research aims to further elucidate the mechanisms underlying DKD progression, paving the way for novel therapies targeting inflammation, fibrosis, and other pathways. These advancements hold promise for improving outcomes and quality of life for DKD patients.

線上課程

-

-

中華民國糖尿病學會乙類1分
社團法人中華民國糖尿病衛教學會乙類2分
台灣內科醫學會乙類1分
社團法人中華民國藥師公會全國聯合會專業1.8積分
家醫計畫2.0時數：DKD 1.5小時
《實際學分數以各醫學會實際通過為主，包含審查中之各醫學會學分》